Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CASP6 | P55212 | 1/20 | 0.50 |
| ▸ | PLAU | P00749 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | NQO2 | P16083 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3364585 | 0.89 | NQO2 (0.50) | LMNAKDM4EGAANQO2MAPT | |
| SCHEMBL4163337 | 0.82 | HSD17B14 (0.50) | KDM4EGAAMAPTHTTALOX15 | |
| SCHEMBL16880740 | 0.82 | HSD17B14 (0.51) | KDM4EMAPTTP53RAB9ASMN1; SMN2 | |
| SCHEMBL4758774 | 0.82 | HTT (0.42) | KDM4EGAANQO2MAPTRAB9A | |
| SCHEMBL9222973 | 0.81 | MAPK1 (0.46) | KDM4EGAANQO2MAPTTP53 | |
| SCHEMBL2004085 | 0.81 | ABCG2 (0.55) | KDM4EGAAMAPTTP53RAB9A | |
| SCHEMBL3361032 | 0.81 | HTT (0.41) | KDM4EGAANQO2MAPTRAB9A | |
| SCHEMBL14339761 | 0.81 | MAPT (0.48) | LMNAKDM4EGAAMAPTRAB9A | |
| SCHEMBL7342388 | 0.81 | HDAC8 (0.55) | KDM4EPOLBMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL31289295 | 0.81 | ABCG2 (0.55) | KDM4EGAAMAPTTP53RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114213394-B | Synthesis method of N-sugar analysis reagent fluorogenic substrate | 上海瀚诺威生物科技有限公司 | 2022-11-08 | — | — | CN | claimed |
| CN-114213394-A | Synthesis method of N-sugar analysis reagent fluorogenic substrate | 上海瀚诺威生物科技有限公司 | 2022-03-22 | — | — | CN | claimed |
| CN-116354879-A | Benzamide derivative and application thereof | 中国药科大学 | 2023-06-30 | — | — | CN | disclosed |
| CN-114213394-B | Synthesis method of N-sugar analysis reagent fluorogenic substrate | 上海瀚诺威生物科技有限公司 | 2022-11-08 | — | — | CN | disclosed |
| CN-114213394-A | Synthesis method of N-sugar analysis reagent fluorogenic substrate | 上海瀚诺威生物科技有限公司 | 2022-03-22 | — | — | CN | disclosed |
| US-11061023-B2 | Fluorescence tagging of glycans and other biomolecules through reductive amination for enhanced MS signals | WATERS TECHNOLOGIES CORPORATION (US) | 2021-07-13 | — | — | US | disclosed |
| US-20190331669-A1 | FLUORESCENCE TAGGING OF GLYCANS AND OTHER BIOMOLECULES THROUGH REDUCTIVE AMINATION FOR ENHANCED MS SIGNALS | WATERS TECHNOLOGIES CORPORATION (US) | 2019-10-31 | — | — | US | disclosed |
| US-7649015-B2 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| CN-101074242-A | Cells accumulation for sphosphonate analogs of HIV protease inhibitor compound and the same compound | GILEAD SCIENCES INC (US) | 2007-11-21 | — | — | CN | disclosed |
| EP-1509537-B9 | CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH | GILEAD SCIENCES INC (US) | 2007-11-14 | — | — | EP | disclosed |
| EP-1509537-B1 | CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH | GILEAD SCIENCES INC (US) | 2007-07-18 | — | — | EP | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
| EP-1711617-A1 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTICS COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005064008-A9 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS | GILEAD SCIENCES INC (US) | 2006-09-28 | — | — | WO | disclosed |
| US-20050239054-A1 | Method and compositions for identifying anti-HIV therapeutic compounds | GILEAD SCIENCES. INC. | 2005-10-27 | — | — | US | disclosed |
| US-20050209197-A1 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. | 2005-09-22 | — | — | US | disclosed |
| CN-1649885-A | Cellular Accumulation of Phosphonate Analogs of HIV Protease Inhibitor Compounds and Such Compounds | GILEAD SCIENCES INC (US) | 2005-08-03 | — | — | CN | disclosed |
| WO-2005064008-A1 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| EP-1509537-A2 | CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH | GILEAD SCIENCES, INC. (US) | 2005-03-02 | — | — | EP | disclosed |
| WO-2003090690-A2 | CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH | GILEAD SCIENCES, INC. (US) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190331669-A1 | FLUORESCENCE TAGGING OF GLYCANS AND OTHER BIOMOLECULES THROUGH REDUCTIVE AMINATION FOR ENHANCED MS SIGNALS | FUT5, FUT6, OGT | LMNA 1541/4885KDM4E 3466/4885POLB 4248/4885 |
| US-20050209197-A1 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | PPA1, PPME1, PNP | LMNA 2684/4885KDM4E 3407/4885POLB 454/4885 |
| US-20050239054-A1 | Method and compositions for identifying anti-HIV therapeutic compounds | CES1, PNP, PGLS | LMNA 3295/4885KDM4E 1006/4885POLB 861/4885 |
| US-11061023-B2 | Fluorescence tagging of glycans and other biomolecules through reductive amination for enhanced MS signals | FUT5, FUT6, OGT | LMNA 1541/4885KDM4E 3466/4885POLB 4248/4885 |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | PPA1, PNP, PPME1 | LMNA 2720/4885KDM4E 3256/4885POLB 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.